Articles tagged with Drug Studies
A clinical trial found that people with severe alcohol disorder stayed off alcohol for longer when treated with low doses of ketamine combined with psychological therapy. The therapy showed promise in preventing relapse and improving liver function, with participants having lower depression rates after three months.
Researchers found that increasing the solution pH makes niclosamide effective against SARS-COV-2 virus replication. A lower dose of niclosamide can also positively affect airway cells without harming them. This could enable safe and effective nose and throat sprays with added protection.
A registry study found that people with inflammatory RMDs, such as rheumatoid arthritis and psoriatic arthritis, tolerate their COVID vaccine well, with short-lived reactions being the most common side effect. The majority of participants were able to continue on their normal medication with no changes.
Researchers found that 48% of patients experienced complete or partial response to pembrolizumab treatment, with two-thirds experiencing clinical response. The study suggests a potential for curative intent in patients with recurrent or metastatic uterine cancer.
A randomized controlled trial involving 51 GP practices and 404 patients found a significant reduction in the number of medicines prescribed for older people with multimorbidity. The intervention group experienced over 800 medicines being stopped, with only mild adverse reactions reported.
Researchers found that chronic use of sildenafil aggravated the development of abdominal aortic aneurysms in mice, disrupting smooth muscle cells' ability to contract. The study suggests caution when prescribing PDE5 inhibitors like sildenafil for patients with existing aortic aneurysmal lesions.
Aspirin use in primary prevention of cardiovascular disease should be individualized based on benefit-to-risk assessment, not age. The authors' updated meta-analysis shows a 13% reduction in cardiovascular disease with similar benefits at older ages.
Researchers found that psilocybin doses of 10mg or 25mg administered simultaneously to up to six participants had no adverse effects. The study also showed promise for treating treatment-resistant depression and PTSD.
A study found that 88% of ED patients with suspected septic olecranon bursitis who received empiric antibiotics without aspiration resolved without needing further treatment. Conservative management may be a reasonable approach for select patients, potentially streamlining care and reducing complications.
Researchers found that Botox-treated patients reported anxiety significantly less often than those undergoing different treatments for similar conditions. The data used was from the FDA's Adverse Effect Reporting System and showed a 22-72% lower risk of anxiety for four out of eight conditions and injection sites.
A new clinical trial is enrolling young people with rare genetic mutations that cause early-onset Alzheimer's disease. The study will test gantenerumab to prevent the buildup of toxic protein amyloid beta, which can slow or stop the disease.
Researchers found that certain bacteria in the human microbiome can produce an enzyme called acarbose kinase, which renders acarbose inactive. This enzyme is present in three major categories of oral and gut bacteria and may make people resistant to the antidiabetic drug.
Families of children with serious illnesses have higher rates of healthcare use and physical/mental health issues compared to those without such conditions. The study included 6,900 children and found significant associations between family health outcomes and the child's condition.
A review suggests that doctors should prescribe fewer antidepressants and for shorter periods due to the potential severity and duration of withdrawal symptoms. The use of antidepressants is also associated with a range of side effects, but clinical trial data often don't assess outcomes that matter most to patients.
Researchers at Tel Aviv University successfully treated autism in animal models with medical cannabis oil, improving behavioral and biochemical parameters. The treatment showed significant improvement in compulsive and anxious behaviors, and a decrease in the concentration of the arousing neurotransmitter glutamate.
A study of 1.1 million patients with type 2 diabetes found disparities in the use of GLP-1 receptor agonists by racial and ethnic groups, as well as by sex and socioeconomic status. The findings highlight concerns about unequal access to effective diabetes care.
A proof-of-concept trial has identified a drug that may offer benefit to some patients hospitalised with COVID-19 pneumonia. The study found namilumab reduced inflammation and improved outcomes in patients with high CRP levels, but further research is needed for definitive results.
A recent study published in JNCCN found that 33 out of 81 studies lacked transparency on censoring, which can introduce bias and affect trial results. The researchers emphasize the need for improved transparency and reporting in clinical trials to ensure patients and clinicians make informed decisions.
New research suggests that cannabis use can lead to harmful drug-drug interactions by interfering with two families of enzymes that metabolize a wide range of drugs. This could result in unintended side effects such as toxicity or accidental overdose, particularly for older individuals using medications.
A new evidence review by Oregon Health & Science University researchers found that the expensive multiple sclerosis drug Acthar provides very little clinical benefit compared to less-expensive alternatives. The study screened 41 studies and found weak or no benefit from Acthar against standard medications like corticosteroids.
Researchers found a novel therapy called AVID200 safe and well-tolerated, with modest improvements in symptom burden, anemia, and spleen enlargement. The therapy needs to be combined with other drugs to optimize impact in patients.
Researchers from Aarhus University have shown that the approved medicine Atovaquone has a protective effect on human lung cells in laboratory settings, potentially preventing Covid-19 infection. The study reveals its potent antiviral properties against various coronavirus variants, offering hope for a new treatment option.
A new NRG Oncology clinical trial found that bupropion did not improve sexual desire in female cancer survivors. The trial evaluated the effects of extended-release bupropion on postmenopausal women with low baseline sexual desire scores.
A recent study found that patients with hormone receptor-positive breast cancer who experience rising ESR1 mutations before disease progression can benefit from an early switch to fulvestrant plus palbociclib. This approach yields a statistically and clinically significant gain in progression-free survival, potentially justifying its a...
A NIH study has identified a molecular link between a gene mutation and late-onset retinal degeneration, a rare eye disease. The researchers found that the diabetes drug metformin and gene therapy may be effective treatments for the condition, which can cause abnormal blood vessel growth and deposits of apolipoprotein E.
A recent study found that pathologic complete response rates did not differ by racial groups, but HR-positive/HER2-negative breast cancer showed a significant survival disparity between Black and white women. The study suggests that tumor molecular subtype is a more significant factor in breast cancer survival than race.
Patients treated with pyrotinib plus capecitabine had a lower risk of death and longer progression-free survival compared to those receiving lapatinib plus capecitabine. Pyrotinib is an irreversible tyrosine kinase receptor inhibitor targeting HER2, EGFR, and HER4.
The Liberty Asthma VOYAGE trial found that dupilumab significantly reduced the rate of severe exacerbations by nearly 60% and improved lung function and asthma control in children ages 6 to 11. Dupilumab was also shown to be safe, with minimal adverse reactions.
A new Australian study has found that taking anxiety drugs like nitrazepam and antidepressants before hip or knee surgery can lead to postoperative delirium. The risk is particularly high for older patients, highlighting the need to adjust medication regimens before undergoing elective procedures.
A study found that US clinical trials of new drugs and biologics lack adequate representation of racial and ethnic populations. The research highlights the need for greater diversity in clinical trial participation to ensure the safety and efficacy of treatments for all patients.
The study used multigene sequencing to identify genomic alterations in patients with metastatic breast cancer. Patients with genomic alterations ranked as ESCAT I/II saw improved progression-free survival with targeted therapies matched to their genomic changes, while those without these alterations did not benefit from the treatment.
In a phase III trial, elacestrant showed significant benefits in decreasing death or disease progression and increasing progression-free survival compared to standard of care. The treatment was well-tolerated with manageable side effects, offering hope for patients with ER-positive/HER2-negative metastatic breast cancer.
A research team developed an AI framework that analyzes protein interactions to predict effective and low-toxicity cancer drug combinations. The framework, GraphSynergy, outperforms conventional models in identifying synergistic combinations.
A new meta-analysis published in the European Journal of Preventive Cardiology suggests that Sodium-glucose co-transporter-2 (SGLT2) inhibitors can improve outcomes for heart failure patients with preserved ejection fraction. The medication has been shown to reduce the risk of death from heart-related causes and hospitalization by 22%.
A new study published in the Journal of Experimental Medicine showed that a fast-tracked stroke drug, 3K3A-APC, protected mice from injury to the brain's white matter, a leading cause of dementia. The drug may also be effective in slowing down progression of cognitive impairment.
A phase 3 clinical trial found that teriflunomide reduced new or enlarged lesions in children with multiple sclerosis, suggesting potential benefits. However, the medication did not delay time to the next clinical relapse.
A study published in the American Journal of Respiratory and Critical Care Medicine found that prostacyclin treatment reduced damage to vital organs and halved mortality rates among critically ill Covid-19 patients. The research team hopes to investigate larger patient populations in future studies.
Researchers at the University of Ottawa have made a breakthrough in reversing memory deficits and slowing disease progression in female mouse models of Alzheimer's disease. The study found that activating a specific receptor was effective in treating females, who make up two-thirds of diagnosed cases.
A Michigan Medicine study found that only 7.4% of patients received naloxone and 8.5% received buprenorphine prescriptions within 30 days of an opioid overdose. The low rates highlight missed opportunities for equipping patients with rescue medicines to use in case of future overdoses.
Researchers developed a predictive model that maps electric activity of mouse, rabbit, and human cardiac cells, allowing translation of findings across species. The model is expected to accelerate drug development and improve understanding of disease mechanisms.
A functional precision medicine study demonstrates that treatment selection based on results from drug sensitivity testing can be clinically useful in patients with aggressive hematological cancer. The approach combines deep molecular profiling with comprehensive drug sensitivity testing to advance the therapy decision-making system.
A Henry Ford Health System study published in The American Journal of Sports Medicine found that a novel opioid-free pain management protocol provided the same pain relief for patients as common types of prescription opioids. This approach aims to reduce opioid misuse and promote more effective pain management after ACL knee reconstruc...
A nationwide study found that hospitalized COVID-19 patients taking immunosuppressive medications did not have a significantly increased risk of dying from COVID-19 or being put on a ventilator compared to non-immunosuppressed patients. However, patients taking rituximab were at a substantially increased risk of death.
A recent study published in Circulation found that patients receiving a combination of antiplatelet drugs for many months (up to 2.5 years) after stent procedures may not receive the full benefit of treatment. The researchers compared characteristics of 8,864 patients from an older trial to 568,540 contemporary patients and determined ...
A phase 2 clinical trial found that losartan, commonly used to treat high blood pressure, did not significantly slow down the progression of Alzheimer's disease in people with mild-to-moderate symptoms. However, the drug may still be beneficial for those with early-stage disease if prescribed for longer periods.
A study with lab-grown mouse cells reveals that lamin C plays a key role in maintaining the structural network under the cell's nucleus, ensuring proper DNA organization. This finding has significant implications for diagnosing and treating genetic disorders linked to DNA disorganization, such as progeria and muscular dystrophy.
A multi-center study assesses medicinal mushrooms and Chinese herbs for therapeutic benefit in treating acute COVID-19 infection. The MACH-19 trial evaluates the safety and feasibility of two investigational compounds, one in capsule form and another as a Chinese herbal formula.
A new anti-diabetic compound, Montbretin A (MbA), has been approved by Health Canada for Phase 1 human trials. MbA works by inhibiting the alpha-amylase enzyme, slowing down starch breakdown and reducing blood sugar spikes in Type 2 diabetics.
Researchers are modifying an arm of a worldwide clinical trial to evaluate a combination of drugs targeting two brain proteins: amyloid and tau. The Tau NexGen Trial aims to test the effectiveness of these treatments in slowing disease progression by targeting both Alzheimer's disease pathologies.
A study published in Translational Psychiatry found that patients with high expectations of SSRI treatment showed a four times higher improvement rate compared to those with low expectations. The effect was attributed to the influence of dopamine on the brain's reward pathways.
Researchers at West Virginia University have received FDA approval for a new drug to treat uveal melanoma, a rare form of eye cancer. The drug, MTI-201, targets specific biomarkers in diseased cells, allowing for more precise treatment with minimal damage to healthy cells.
Scientists from Japan discover IL-36Ra plays a pivotal role in wound healing, and Cl-amidine normalizes exacerbated I/R injury. The study's findings suggest IL-36Ra as a potential therapeutic target for cutaneous I/R injuries.
Researchers have discovered that a low-dose oral compound, HBI-002, can safely reduce oxidative stress and inflammation in the retina, common causes of diabetic retinopathy. The study suggests that small amounts of carbon monoxide may help protect vision in diabetes patients.
Researchers at Mount Sinai have developed a diverse library of well-characterized human induced pluripotent stem cell lines from clinically healthy individuals, offering valuable resources for studying normal human biology, evaluating drug responses, and disease modeling.
Trials that met their primary endpoint were more commonly published in journals with higher impact factors, suggesting a correlation between trial outcome and publication quality. Additionally, publications of trials leading to FDA approvals and those in high-impact journals were associated with increased Research Citation Rates.
A recent survey of advanced breast cancer patients in the UK reveals that only 14% have been recruited to a trial, highlighting a need for improved access. Patients often face barriers, including clinician reluctance to discuss trials and a lack of patient-friendly databases.
A new analysis finds that 67 million US adults identify as disabled, with significant disparities among different socioeconomic and demographic groups. The study highlights the need for accurate data on disability to inform effective policies and solutions.
Researchers at Johns Hopkins Medicine found that antibody levels against SARS-CoV-2 stay higher in people who were infected by the virus and then received protection from mRNA vaccine compared to those who only got vaccinated. A longer interval between virus exposure and first vaccine dose may enhance antibody response.
Itepekimab, a novel monoclonal antibody, has been found to be safe and effective in treating moderate-to-severe asthma. In a phase 2 trial, it significantly improved lung function and reduced asthma control events compared to placebo.
A five-year study aims to identify hormone responses in a population of Mexican Americans with prediabetes, Type 2 diabetes, and obesity. The research uses genetic data and physiologic testing to guide optimal treatments for diabetes, prediabetes, and related diseases.